Zacks upgrades Collegium Pharmaceutical stock to strong buy
Published on 10/17/2026 at 20:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and upcoming results
- Zacks Research upgraded Collegium Pharmaceutical from strong sell to strong buy on October 17, 2026.
- Collegium Pharmaceutical had a trailing P/E ratio of 18.70 on October 16, 2026.
- Collegium Pharmaceutical stock costs EUR 19.50 at 10:44 a.m. CEST on October 17, 2026, up 0.52 percent versus the gettex close of October 16, 2026.
- Collegium Pharmaceutical is scheduled to report results on November 5, 2026.
MarketBeat reported on October 17, 2026 that Zacks Research upgraded Collegium Pharmaceutical from strong sell to strong buy. The gettex quote was EUR 19.50 on October 17, 2026 at 10:44 a.m. CEST, up 0.52 percent versus the gettex close of October 16, 2026.
Valuation stays measurable
Collegium Pharmaceutical had a trailing price-to-earnings ratio of 18.70 on October 16, 2026. Market capitalization stood at USD 755.0 million on the same date. The company operates in specialty pharmaceuticals, with medicines focused on pain management and neuropsychiatry.
The quote was positioned near the lower end of the primary-market range. On October 16, 2026, the Nasdaq range ran from USD 21.43 to USD 50.79, leaving the share price USD 2.24 above the low and USD 27.60 below the high. The stock traded at USD 23.19 at the Nasdaq close on October 16, 2026, with 558,644 shares changing hands, according to MarketBeat.
Results date adds a calendar marker
Collegium Pharmaceutical is scheduled to report its next results on November 5, 2026, according to MetaCap. The calendar date gives the rating change a defined event horizon, while the current valuation can be compared with the next reported period.
Comparison with peers
Collegium Pharmaceutical (Nasdaq, USD): up 0.52 percent, P/E 18.70, market capitalization USD 755.0 million
Pfizer (NYSE, USD): up 0.48 percent, P/E 39.09, market capitalization USD 168.6 billion
Bristol-Myers Squibb (NYSE, USD): minus 1.35 percent, P/E 13.16, market capitalization USD 122.1 billion
Price remains the market frame
The gettex quote showed EUR 19.50 on October 17, 2026 at 10:44 a.m. CEST, up 0.52 percent versus the gettex close of October 16, 2026. The bid was EUR 19.40 and the ask EUR 19.80 on October 17, 2026 at 10:36 a.m. CEST.
Collegium Pharmaceutical market data
- Company: Collegium Pharmaceutical, Inc.
- ISIN: US19459J1043
- Ticker: COLL
- Primary exchange: Nasdaq
- Price gettex (as of October 17, 2026, 10:44 a.m. CEST): EUR 19.50
- Change versus gettex close: plus 0.52 percent
- Gettex close (October 16, 2026): EUR 19.40
- Market capitalization: USD 755.0 million (as of October 16, 2026)
- 52-week range: USD 21.43-50.79 (as of October 16, 2026)
- Next earnings date: November 5, 2026
Market context: Market report Nasdaq Composite.
